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Conventional measurement of blood pressure (BP) in indi-vidual patient care has several limitations that include 
causing spurious elevation of BP (white-coat hypertension) or 
giving normal readings when, in fact, the patient is hypertensive 
(masked hypertension).1 Out-of-office BP measurements using 
home BP monitoring (HBPM) or ambulatory BP monitoring 
(ABPM) provide insight into the true behavior of BP in individ-
ual patients during various daily activities at home and at work 
and during sleep (with ABPM). Although it is acknowledged 
at the outset that masked phenomena are a consequence of the 
methodology of BP measurement, the condition, nevertheless, 
has serious consequences for the diagnosis and management of 
patients with hypertension. Recent advances in our understand-
ing of masked hypertension will be examined in this review.
Definitions
Conventional BP in the office or clinic is considered to be nor-
mal if it is <140/90 mm Hg. In contrast, out-of office BP val-
ues must take into consideration the period of the day simply 
because BP levels are different during the day and night, and 
BP may be elevated during either of these periods or throughout 
the 24-hour period. Indeed the 24-hour period can be further 
subdivided into the white-coat window (generally the first hour 
and possibly also the last hour) when the patient is subject to 
the influence of the medical environment, and the preawakening 
period when the subject may exhibit a morning surge in BP.1,2
Current consensus guidelines define out-of office hyperten-
sion as daytime BP ≥135/85 mm Hg, nighttime BP ≥120/70 
mm Hg, and 24-hour average BP ≥130/80 mm Hg (Table 1).1
The daytime cutoff BP values for hypertension pertain to 
both ABPM and HBPM. Thus, for daytime measurements, 
the definition of masked hypertension in untreated individu-
als is an in-office BP of <140/90 mm Hg and an out of-office 
BP of ≥135/85 mm Hg. However, as shown in Table 1, out-
come-driven ABPM and HBPM cutoff values are generally 
lower than consensus numbers, mainly reflecting the impor-
tance of cardiovascular risk in masked hypertensives that are 
captured—predominantly in the prehypertension category and 
occasionally in those with optimal BP.1–5 Indeed, risk stratifi-
cation by ABPM across Joint National Classification BP cate-
gories, using the International Database on Ambulatory Blood 
Pressure in Relation to Cardiovascular Outcomes (IDACO) 
meta-analysis population adjusted for covariables (Figure 1), 
unmasked masked hypertension in 7.5% and 29.3% of individ-
uals with normotension and prehypertension, respectively.6,7 
The term masked hypertension is reserved for antihyperten-
sive naïve patients. In patients with treated hypertension, the 
presence of residual masked hypertension is called masked 
uncontrolled hypertension (MUCH).
Conditions in Which Masked  
Hypertension Is Likely
Elderly patients with a male predominance who present with 
increased BP variability are more likely to have masked 
hypertension than sustained normotension or white-coat 
hypertension.8 Conventional office measurement of BP in an 
elderly hypertensive patient soon after a large meal may pro-
duce postprandial reduction of BP and a diagnosis of masked 
hypertension.9 Mental stress at work or at home may raise BP 
to hypertensive levels except at the time of conventional office 
measurements.10,11 Smokers and patients who consume exces-
sive alcohol are prone to masked hypertension.12,13 Sedentary, 
obese individuals may have poor exercise tolerance through-
out the day’s activities, whereas they record prehypertensive 
BP values in the physician’s office when measured at rest.14,15 
Finally, the presence of metabolic syndrome, diabetes mellitus, 
chronic kidney disease, shortened sleep time, or obstructive 
sleep apnea may predispose to masked hypertension largely 
because of nocturnal hypertension.16–20 Indeed, elevated night-
time BP and nondipping or rising nocturnal BP patterns, with 
or without elevated daytime ABPM values, may be associated 
with normal conventional office BP values, and hence with a 
diagnosis of masked hypertension.20–22 In summary, there is 
a need for 24-hour ABPM with assessment of both day and 
nighttime BP to diagnose masked hypertension in the many 
conditions where it might occur.
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Progression of Masked Hypertension
There is moderately good prediction and persistence of 
masked hypertension when patients with prehypertension are 
screened by conventional office measurements.23 Pickering 
et al,24 early after first describing the entity, thought that 
masked hypertension, alternating with prehypertension, was 
a precursor to sustained hypertension. However, a 5-year 
Quebec population study assessed the persistence of masked 
hypertension and its progression to sustained hypertension.25 
Among patients with baseline masked hypertension, more 
than half had either masked or sustained hypertension at 5 
years, many of whom were started on antihypertensive treat-
ment; one third progressed to sustained hypertension, one 
third regressed to normotension, and 1 in 5 remained masked 
>5 years when not treated. Indeed, delay in making the 
diagnosis of masked hypertension may account for the high 
prevalence of hypertensive cardiovascular target organ dam-
age.21,22,26,27 Furthermore, treated patients with MUCH tend to 
have persistent target organ damage that is comparable with 
what is observed in patients with sustained hypertension.27
Prevalence of Masked Hypertension
The frequency of masked hypertension varies considerably 
depending on population characteristics and the presence 
or absence of antihypertensive treatment. In the 11-country 
IDACO report of middle-aged and elderly patients (mean age, 
64 years), using daytime ABPM, 1168 untreated patients had 
isolated systolic hypertension: of this total, 314 (26.9%) had 
sustained hypertension, 334 (28.5%) had white-coat hyperten-
sion, and 520 (44.5%) had masked hypertension28; importantly, 
masked isolated systolic hypertensives represented 9.0% of 
the conventional normotensive group.28 In another 11-country 
IDACO report, including 9691 subjects drawn from the general 
population, nondiabetic patients who were normotensive on 
conventional measurement had a masked hypertension preva-
lence of 18.8%, when untreated and 30.5% with treatment 
(Table 2).17 In contrast, conventionally normotensive diabetic 
patients had a prevalence of masked hypertension of 29.3% 
when untreated and 42.5% with treatment.17 Thus, the preva-
lence of masked hypertension not only rises in the presence of 
diabetes mellitus and in many other high-risk disease states but 
also is influenced by antihypertensive treatment.
Increased Prevalence of MUCH
In most published reports, the prevalence of masked hyper-
tension is higher in antihypertensive treated when compared 
with untreated patients; we noted these findings in a recent 
IDACO study17 (Table 2); the reasons need to be examined. 
Antihypertensive treatment on average will lower ABPM val-
ues by 60% to 70% of the reduction of conventional in-office 
BP, ie, approximately a 3 mm Hg systolic BP (SBP) reduction 
of conventional in-office BP for a 2 mm Hg SBP reduction 
in out-of-office ABPM.29,30 More recently, Schmieder et al31 
noted that patients with higher pretreatment SBP levels had an 
even greater disproportional reduction in office SBP than in 
ambulatory SBP after undergoing antihypertensive treatment; 
in addition, these investigators31 and others32,33 noted that the 
white-coat effect decreased by ≈10/5 mm Hg on average after 
Table 1. Ambulatory and Home Blood Pressure Values 
(mm Hg)
Category Interval Optimal, mm Hg Normal, mm Hg Elevated, mm Hg
ABPM
  Consensus Daytime ... ... ≥135/85
  Population Daytime <120/80 <130/85 ≥140/85
Home
  Consensus Daytime ... ... ≥135/85
  Population Daytime <120/75 <125/80 ≥130/85
ABPM
  Consensus Nighttime ... ... ≥120/70
  Population Nighttime <100/65 <110/70 ≥120/70
ABPM
  Consensus 24-h ... ... ≥130/80
  Population 24-h <115/75 <125/75 ≥130/80
Consensus and population denote consensus-based and population-based 
threshold, respectively. ABPM (consensus-based)1; ABPM (population-based)3; 
home (consensus-based)4; and home (population-based)5. ABPM indicates 
ambulatory blood pressure monitoring.
Figure 1. Hazard ratios (HRs) for cardiovascular events and strokes associated with masked hypertension in subjects with normotension 
(<120/<80 mm Hg) or prehypertension (120–139/90–89 mm Hg) according to their conventional blood pressure.6 Participants with 
sustained normotension are the reference group. HRs are obtained from the IDACO (International Database on Ambulatory Blood 
Pressure in Relation to Cardiovascular Outcomes) database and are adjusted for cohort, sex, age, body mass index, smoking and 
drinking, cholesterol, diabetes mellitus, and history of cardiovascular complications. Reprinted from Brguljan-Hitij et al6 with permission of 
the publisher. Copyright © 2014, the Oxford University Press.
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beginning antihypertensive treatment, but was still present 
after 1 year, thus contributing to the reduction of in-office 
BP but not in ABPM. Perhaps of equal importance, a morn-
ing recording of normal in-office BP may be at peak levels of 
medication while trough levels later in the day and night may 
be associated with hypertensive BP values. Regardless of the 
mechanisms for the disproportional greater reduction in office 
than in ambulatory BP, the important message for physicians 
is that treatment aimed at normalizing conventional office BP 
will increase the percentage of patients with MUCH.
Increased Cardiovascular Risk of MUCH
Not only does antihypertensive treatment increase the preva-
lence of MUCH but also treatment increases its cardiovascular 
risk. The effects of antihypertensive treatment versus no treat-
ment on the cardiovascular risk of sustained hypertension, 
masked hypertension, and sustained normotension in a non-
diabetic population are illustrated in a recent IDACO study 
(Figure 2).17 There was increased cardiovascular risk in both 
the treated masked uncontrolled hypertensives and the treated 
normotensive patients in comparison with the untreated 
masked hypertensives and untreated sustained normotensive 
groups, respectively.17 The logical explanation for these find-
ings is that some patients with sustained hypertension were 
converted into masked hypertension and some of the masked 
hypertension patients were converted into sustained normo-
tension. These findings illustrate the epidemiological princi-
ple that normalization of BP with treatment does not eliminate 
lifetime burden associated with previous elevated BP (risk, in 
part, being dependent on the duration of hypertension), or 
does it correct the other metabolic risk factors that cluster with 
the hypertensive state.
The high prevalence of MUCH among treated subjects sug-
gests that most physicians use suboptimal antihypertensive 
treatment, largely because they focus primarily on normalizing 
conventional office BP values. In summary, the conventional 
normalization of office BP with antihypertensive treatment 
will leave a significant number of patients with undetected 
MUCH. In contrast, optimal treatment that uses out-of-office 
BP monitoring will decrease MUCH by maximal conversion 
to sustained normotension.
Diagnostic Strategies for Masked Hypertension
Although automated office monitoring of BP is superior to 
conventional office BP monitoring, it cannot provide a profile 
of BP over 24 hours as with ABPM or track BP for multiple 
days, weeks, and months as with HBPM.34–37 Importantly, a 
meta-analysis done by Hodgkinson et al38 concluded that nei-
ther office nor HBPM had sufficient sensitivity nor specificity 
to replace ABPM as the reference standard. A further advan-
tage of ABPM over HBPM is the ability to identify patients 
with normal daytime but nocturnal masked hypertension. In 
addition, many of ABPM readings are taken during normal 
daily activity, whereas HBPM readings are always taken at 
rest. Consequently, it has been recommended that a positive 
diagnosis of masked hypertension be confirmed by ABPM 
before commencing antihypertensive therapy.1,39,40.
Treatment Strategies for Sustained 
Hypertension
Del la Sierra et al41 followed up 2115 treated hypertensive 
patients from the Spanish ABPM registry for a 4-year duration 
for cardiovascular events. After adjustment for baseline car-
diovascular risk and office BP, nighttime but not daytime SBP 
predicted cardiovascular events (hazard ratio per SD increase, 
1.45; 95% confidence interval, 1.29–1.59). Thus, nighttime 
BP was the single most important predictor of cardiovascular 
risk.41 Using an updated database from The Spanish Society 
of Hypertension ABPM Registry, Banegas et al42 identified 
31% of patients who had MUCH by 24-hour ABPM (MUCH) 
among the 14 840 subjects with treated and controlled con-
ventional BP. These patients were well controlled to prehyper-
tensive BP levels with conventional in-office BP monitoring. 
The clinical characteristic of MUCH patients were male 
sex, advanced age, obesity, smoking history, diabetes mel-
litus, and longer duration of hypertension—characteristics 
that increased the risk of future cardiovascular disease.42 
Importantly, poorer control of nocturnal BP was twice as fre-
quent as daytime ABPM control in defining MUCH and was 
Table 2. Prevalence of Masked Hypertension by Treatment Status in Diabetics and Nondiabetics
Treatment Status
Prevalence, % Odds Ratio
Nondiabetics Diabetics Unadjusted Partly Adjusted Fully Adjusted
Untreated 18.8% (1031/5486) 29.3% (67/229) 1.79 (1.33−2.40); P<0.001 1.46 (1.08−1.98); P=0.014 1.35 (0.98−1.86); P=0.065
Treated 30.5% (192/630) 42.5% (37/87) 1.69 (1.07−2.67); P=0.025 1.59 (1.00−2.52); P=0.051 1.59 (0.98−2.58); P=0.058
Partly adjusted odds ratios are adjusted for sex and age only. Fully adjusted odds ratios are adjusted for sex, age, conventional systolic blood pressure, history of 
cardiovascular complications, current smoking status, current alcohol intake, body mass intake and total cholesterol. Reprinted from Franklin et al.17
Figure 2. Cohort, sex, and age-standardized incidence of 
cardiovascular events in untreated and treated normotensive (NT) 
and masked hypertensive (MHT) nondiabetic subjects that are 
derived from an IDACO (International Database on Ambulatory 
Blood Pressure in Relation to Cardiovascular Outcomes) meta-
analysis.17 Fully adjusted hazard ratios (HRs) for treated vs untreated 
masked hypertensives are as follows: HR, 2.27 (95% confidence 
interval, 1.6–3.2; P<0.0001). Adapted from Franklin et al.17
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the exclusive abnormality in 24% of patients. Indeed, many 
patients with resistant MUCH had persistent failure to control 
nighttime hypertension.
Furthermore, Banegas et al43 suggest that the lack of ben-
efit of antihypertensive treatment in some randomized con-
trol trials may partly result from excluding some patients with 
masked hypertension and including some patients with white-
coat hypertension at trial baseline. Consequently, the use of 
ABPM in clinical trials may lead to a better assessment of 
trial eligibility.43
Treatment Strategies for Masked Hypertension
There is strong evidence that masked hypertension patients 
have increased risk of target organ damage, cardiovascular, 
and renal morbidity1,27,44 with an overall cardiovascular risk 
approaching that of sustained hypertensives27; therefore, one 
can make a good case for starting antihypertensive therapy 
when the diagnosis of masked hypertension has been substan-
tiated. What is lacking, however, is a randomized controlled 
trial that assesses the optimal level of daytime and night-
time BP reduction to weigh therapeutic benefits versus car-
diovascular risks. There are additional questions that remain 
unanswered: 1) Because in-office BPs are already well within 
normal guidelines in patients with masked hypertension, 
is there a limit to further reduction in-office BP that would 
pose a cardiovascular risk? (2) Will the benefit of active drug 
treatment in reducing hypertensive target organ damage and 
cardiovascular events be similar in patients with masked 
hypertension as in those with sustained hypertension?
Perspective
Whereas masked hypertension is a consequence of the meth-
odology of BP measurement, the condition, nevertheless, has 
serious consequences for the diagnosis and management of 
patients with hypertension. Not only does masked hyperten-
sion occur in a multitude of diverse clinical settings that on 
frequent occasions elevate BP more often at night than dur-
ing the day but also these associated medical conditions are at 
high risk for future cardiovascular disease events. Importantly, 
initiating antihypertensive treatment with only conventional 
office BP assessment may transition sustained hypertension 
into a high percentage of MUCH, rather than the desired 
therapeutic goal of sustained normotension. Quantitatively, 
the exclusive use of in-office BP to determine how low to 
go will undertreat ≈1 out of 3 patients who will be left with 
MUCH. Importantly, 2 out of 3 of these insufficiently treated 
patients will have nocturnally driven masked hypertension 
that requires ABPM for detection. Therefore, although HBPM 
may be the preferred diagnostic method of assessing out-of-
office BP during the initiation and dose-titration of antihyper-
tensive therapy, the use of ABPM will be necessary to rule 
out undiagnosed nocturnal masked hypertension. Importantly, 
undiagnosed and untreated masked hypertension and treated 
but uncontrolled masked hypertension represent 2 signifi-
cant high-risk populations of public health concern. Indeed, 
current evidence strongly supports revision of National and 
International guidelines that base diagnostic and therapeutic 
decisions on patient’s age and conventional in-office levels; 
these measurements should be supplemented with HBPM and 
ABPM to address the current worldwide poor control-rate of 
hypertension.
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